CORONA VIRUS COVID-19 VACCINE - WHERE ARE WE NOW? update ng Corona Virus Vaccine as of June 17, 2020

 Coronavirus Vaccine Tracker

 By Jonathan Corum, Denise Grady and Carl ZimmerUpdated June 17, 2020

PRECLINICAL

PHASE I

PHASE II

PHASE III

APPROVAL

125

8

8

2

0

Vaccines

not yet in

human trials

Vaccines

testing safety

and dosage

Vaccines

in expanded

safety trials

Vaccines

in large-scale

efficacy tests

Vaccines

approved

for use

Researchers around the world are developing more than 135 vaccines against the coronavirus. Vaccines typically require years of research and testing before reaching the clinic, but scientists are racing to produce a safe and effective vaccine by next year.

Antibody

produced in

response to a

vaccine

SARS-CoV-2

coronavirus

Work began in January with the deciphering of the SARS-CoV-2 genome. The first vaccine safety trials in humans started in March, but the road ahead remains uncertain. Some trials will fail, and others may end without a clear result. But a few may succeed in stimulating the immune system to produce effective antibodies against the virus.

Here is the status of all the vaccines that have reached trials in humans, along with a selection of promising vaccines still being tested in cells or animals.

The Vaccine Testing Process

The development cycle of a vaccine, from lab to clinic.

PRECLINICAL TESTING: Scientists give the vaccine to animals such as mice or monkeys to see if it produces an immune response.

PHASE I SAFETY TRIALS: Scientists give the vaccine to a small number of people to test safety and dosage as well as to confirm that it stimulates the immune system.

PHASE II EXPANDED TRIALS: Scientists give the vaccine to hundreds of people split into groups, such as children and the elderly, to see if the vaccine acts differently in them. These trials further test the vaccine’s safety and ability to stimulate the immune system.

PHASE III EFFICACY TRIALS: Scientists give the vaccine to thousands of people and wait to see how many become infected, compared with volunteers who received a placebo. These trials can determine if the vaccine protects against the coronavirus.

APPROVAL: Regulators in each country review the trial results and decide whether to approve the vaccine or not. During a pandemic, a vaccine may receive emergency use authorization before getting formal approval.

WARP SPEED: The U.S. government’s Operation Warp Speed program has selected five vaccine projects to receive billions of dollars in federal funding and support before there’s proof that the vaccines work.

COMBINED PHASES: Another way to accelerate vaccine development is to combine phases. Some coronavirus vaccines are now in Phase I/II trials, for example, in which they are tested for the first time on hundreds of people.

Genetic Vaccines

Vaccines that use one or more of the coronavirus’s own genes to provoke an immune response.

DNA

RNA

PHASE II WARP SPEED

Moderna’s vaccine dazzled the stock market in May with Phase I data on just eight people, only to see its stock price drop when experts had a lukewarm reaction to the results. The vaccine uses messenger RNA (mRNA for short) to produce viral proteins. Part of Operation Warp Speed, the American company is eyeing Phase III trials in July and hopes to have vaccines ready by early 2021.

PHASE I PHASE II WARP SPEED

The German company BioNTech has entered into collaborations with Pfizer, based in New York, and the Chinese drug maker Fosun Pharma to develop their mRNA vaccine. In May, Pfizer announced human trials for the vaccine. Another beneficiary of Operation Warp Speed, Pfizer hopes to have a few million doses for emergency use in the fall if all goes well in the trials.

PHASE I PHASE II

Imperial College London researchers have developed a “self-amplifying” RNA vaccine, which boosts production of a viral protein to stimulate the immune system. They began Phase I/II trials on June 15 and have partnered with Morningside Ventures to manufacture and distribute the vaccine through a new company called VacEquity Global Health.

PHASE I

In May, the American company Inovio published a study showing that their DNA-based vaccine produced antibodies in mice. Phase I trials are underway in the United States and will start in South Korea at the end of June.

PRECLINICAL

In March, the Trump administration tried to entice CureVac to move its research from Germany to the United States. On June 17, the company announced approval for a Phase I trial of its mRNA vaccine. The company said its German facility can make hundreds of millions of vaccines a year.

Viral Vector Vaccines

Vaccines that use a virus to deliver coronavirus genes into cells and provoke an immune response.

PHASE II PHASE III WARP SPEED

A vaccine in development by the British-Swedish company AstraZeneca and the University of Oxford is based on a chimpanzee adenovirus called ChAdOx1. The vaccine is beginning Phase II/III testing in England and Brazil. Supported by Operation Warp Speed, the project may deliver emergency vaccines by October. In June, AstraZeneca said their total manufacturing capacity stands at two billion doses.

PHASE II

The Chinese company CanSino Biologics is testing a vaccine based on an adenovirus called Ad5, in partnership with the Institute of Biology at the country’s Academy of Military Medical Sciences. In May they published a paper in The Lancet, the first time Phase I trial data from any Covid-19 vaccine appeared in a scientific journal.

PRECLINICAL WARP SPEED

Researchers at Beth Israel Deaconess Medical Center in Boston are testing an adenovirus called Ad26 in monkeys. Johnson & Johnson, picked by Operation Warp Speed, announced in June that they would start Phase I/II trials in late July.

PRECLINICAL

The Swiss company Novartis will manufacture a vaccine based on a gene therapy treatment developed by the Massachusetts Eye and Ear Hospital. A virus called an adeno-associated virus delivers coronavirus gene fragments into cells. Phase I trials are set to begin in late 2020.

PRECLINICAL WARP SPEED

The American company Merck announced in May it would develop a vaccine from vesicular stomatitis viruses, the same approach it successfully used to produce the only approved vaccine for Ebola. The company is partnering with IAVI.

PRECLINICAL

Merck is also working with Themis Bioscience, an Austrian firm it is acquiring, to develop a second vaccine, which will use the measles virus to carry genetic material into patients’ cells.

PRECLINICAL

Vaxart’s vaccine is an oral tablet containing an adenovirus that delivers coronavirus genes. In June, the American company announced it was preparing for Phase I trials in summer 2020.

Protein-Based Vaccines

Vaccines that use a coronavirus protein or a protein fragment to provoke an immune response.

PHASE I PHASE II

In May, the Maryland-based Novavax started a Phase I/II trial on a vaccine made up of microscopic particles carrying fragments of coronavirus proteins. The Coalition for Epidemic Preparedness Innovations is investing $384 million in the project.

PHASE I

Clover Biopharmaceuticals has developed a vaccine containing a protein from coronaviruses. The vaccine would be taken in conjunction with a so-called adjuvant, made by the British drugmaker GSK, to further stimulate the immune system.

PRECLINICAL

After the SARS epidemic in 2002, Baylor College of Medicine researchers began developing a vaccine that could prevent a new outbreak. Despite promising early results, support for the research disappeared. Because the coronaviruses that cause SARS and Covid-19 are very similar, the researchers are reviving the project in partnership with the Texas Children’s Hospital.

PRECLINICAL

A vaccine in development by the University of Pittsburgh, called PittCoVacc, is a skin patch tipped with 400 tiny needles made of sugar. When placed on the skin, the needles dissolve and deliver virus proteins into the body.

PRECLINICAL

A vaccine from Australia’s University of Queensland delivers viral proteins altered to draw a stronger immune response. In June, the university and the company CSL announced a partnership to start Phase I trials, which could lead to millions of doses a year starting in 2021. GSK is providing an adjuvant to further stimulate the immune system.

PRECLINICAL

The French company Sanofi will produce viral proteins using engineered viruses that grow inside insect cells. GSK will supplement these proteins with adjuvants that stimulate the immune system. Sanofi has said it could produce at least 600 million doses a year if the vaccine succeeds in trials.

Whole-Virus Vaccines

Vaccines that use a weakened or inactivated version of the coronavirus to provoke an immune response.

Inactivated

virus

PHASE I PHASE II

The private Chinese company Sinovac Biotech is testing an inactivated vaccine called CoronaVac. On June 13 the company announced that Phase I/II trials on 743 volunteers found no severe adverse effects and produced an immune response. Sinovac is preparing Phase III trials in China and Brazil and is building a facility to manufacture up to 100 million doses annually.

PHASE I PHASE II

The state-owned Chinese company Sinopharm has started Phase I/II trials on two inactivated vaccine viruses. The company has announced it has built a facility in Beijing to make up to 200 million vaccines per year.

PHASE I

Researchers at the Institute of Medical Biology at the Chinese Academy of Medical Sciences, which has invented vaccines for polio and hepatitis A, are running a Phase I trial of an inactivated virus vaccine for Covid-19.

Repurposed Vaccines

Vaccines already in use for other diseases that may also protect against Covid-19.

PHASE III

The Bacillus Calmette-Guerin vaccine was developed in the early 1900s as a protection against tuberculosis. The Murdoch Children’s Research Institute in Australia is conducting a Phase III trial, and several other trials are underway to see if the vaccine partly protects against the coronavirus.

 ref:  https://www.nytimes.com/interactive/2020/science/coronavirus-vaccine-tracker.html

june 14, 2020

My purpose in life is to serve our clients in the manufacturing & related industries in the Philippines, for a greater self-sufficient industrialized Philippines..

serve my clients, my bosses & principals, My co-workers, 

while ensuring the safety & health of my family 

A sense of purpose could prolong your life

May 26, 2019

By Ephrat Livni

Senior reporter, law & politics, DC.

Quartz Daily Brief

The meaning of life is a question that has plagued philosophers for millennia, and there is no single correct answer. But increasingly, scientists are finding that having a sense of purpose, whatever yours may be, is key to well-being.

Now, a study published on May 24 in JAMA Current Open adds to the growing body of knowledge on the link between health and a driving force, finding that purposefulness is tied to longer lives. Researchers from the University of Michigan School of Public Health analyzed data from nearly 7,000 individuals over 50 years old and concluded that “stronger purpose in life was associated with decreased mortality.” They believe that “purposeful living may have health benefits.”

The new research relied on data from individuals who enrolled in the American Health and Retirement Study (HRS)—longterm research that looks at a cross-section of subjects over time. The original research measured participants’ psychological well-being in 2006, their physical health and, subsequently, causes of death by 2010. The new analysis found that those whose psychological questionnaires reflected a lack of purpose were more likely to die than those who had “a self-organizing life aim that stimulates goals.”

In fact, people without a purpose were more than twice as likely to die than those with an aim and goals. Purpose proved to be more indicative of longevity than gender, race, or education levels, and more important for decreasing risk of death than drinking, smoking, or exercising regularly.

Notably, the research indicates that any purpose is better than none, as the reason people felt purposeful didn’t figure into the analysis. So it doesn’t seem to matter what it is that drives an individual, whether it’s a passion for growing peonies, say, or wanting to see their children develop, or loving the work they do. The important thing is simply having something that makes them excited about life and drives them.

But those who feel no sense of purpose now shouldn’t despair because that drive can be cultivated, as the study notes. “There are a number of interventions that have been developed with the goal of improving life purpose,” the researchers write. They point to previous analyses that have found volunteering, well-being therapy, meditation, and mindfulness training have all been shown to cultivate a greater sense of purpose, improve quality of life, and influence physical health.

Future work should examine when such interventions are appropriate in people diagnosed with diseases and, the researchers argue, purposefulness training could be integrated into treatment approaches. They note that their conclusions are consistent with work done in Japan measuring the concept of ikigai, which is defined as “something to live for, the joy and goal of living” and has been associated with survival.

Although there has been work done on purpose and longevity before, the latest findings surprised even the researchers who devised this latest study. Celeste Leigh Pearce, an associate professor of epidemiology at the University of Michigan and a co-author of the paper, tells NPR, “I approached this with a very skeptical eye. I just find it so convincing that I’m developing a whole research program around it.”

Repost from:

https://qz.com/1628452/a-sense-of-purpose-could-prolong-your-life/#:~:text=In%20fact%2C%20people%20without%20a,%2C%20smoking%2C%20or%20exercising%20regularly.

Ms. Caryl Maderaje

my friend, my bes, my crush, my drinking buddy, sobrang love ko to, bait kasi..at ang ganda pa..nakaka inlove siya kasama, at pag nakita mo siya, nakaka increase ng immune system..hahaha

photos taken from her social media account:
IG= caryl_maderaje
FB= Caryl Maderaje
Twitter=  @crylmdrj

Ms. Sue Ramirez 2020 beach photos

thank you for the inspiration & hope Ms Sue Ramirez...In this time of uncertainty, you are certainly so hot & an awesome distraction..

Ms. Sue Ramirez

 

 

  

 photos taken from her social media account

FB= @sueannadoodles

IG= sueannadoodles

Twitter= @sueanna_dodd

HAY BUHAY SENATOR KIKO PANGILINAN -GIGIL MOKO!

politically neutral na po ako gawa ng napagsabihan ako ng mga trusted friends ko na wag na masyado magmema sa politika...idol ko si Pres Duterte, pro ako saludo din ako ke VP Robrero kasi very hardworking yung office of the VP..

Pero nakikita ni Sen. Pangilinan yung around 20-30 police dun sa Mananita ni Gen. Sinas...pero hindi nya nakita yung mahigit 200-300 na nagprotesta sa UP Diliman..pag ba sa UP Diliman nag mass gathering/rally exempted sa batas??? at least yung rally sa UPLB naka social distancing..yung sa UP Diliman ba? hays...TAMA NA POLITIKA KIKO, BATAS MO PALPAK PA..hay.. kaya ni isa sa inyo walang nanalo sa senado eh...

wag nyo lasunin isip ng mga kabataan at hikayatin magrally rally, hayaan nyo nalang sila mag enjoy magtiktok or mag ML pra at least STAY AT HOME! or mag online selling at least business minded!

Ms. Kim Domingo

Ms. Kim Domingo @therealkimdomingo #BENCHBody